At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
Antroquinonol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19
In Brief
A Phase 2 clinical trial evaluating Antroquinonol and Placebo for Covid-19. Completed, enrolled 124 participants across 15 sites in 3 countries.
Detailed Summary
To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid-19
CountriesArgentina, Peru, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartOct 2020
Primary CompletionDec 2021
TodayJul 2026
First PostedAug 21, 2020
Enrollment StartOct 15, 2020
Primary CompletionDec 23, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.9 years ago
Interventions
Antroquinonoldrug
double-blind for antroquinonol and Placebo with same out-look and same frequency.
Placeboother
Capsule without active compound